Summary
Introduction
Cytarabine liposome injection (DepoCyt®), a sterile suspension of the antimetabolite cytarabine, encapsulated into multivesicular, lipid-based particles, has been developed to improve the treatment of neoplastic meningitis (NM) through sustained release of cytarabine. The objective of this study was to determine the pharmacokinetics (PK) of cytarabine after intrathecal administration of 50 mg encapsulated cytarabine (DepoCyt®) in patients with neoplastic meningitis up to 336 h (14 days) after dosing.
Methods
This was an open-label study wherein two 50-mg doses of DepoCyt® were administered 14 days apart via the intraventricular (IVT) route or by lumbar puncture (LP). Cerebrospinal fluid (CSF) samples were collected from eight adult patients at various times up to 14 days after each dose. Plasma samples were also collected within the same time period. CSF samples were analyzed for unencapsulated (free) and encapsulated cytarabine and the cytarabine metabolite, ara-U. Plasma samples were analyzed for free cytarabine and ara-U. The limit of detection was 0.003 μg/mL cytarabine and 0.016 μg/ml for ara-U.
Results
The concentration of free and encapsulated cytarabine in the ventricular and lumbar CSF ranged from 0.01 to 1500 μg/mL and were detectable up to 14 days post-dosing. Free cytarabine concentrations in plasma were only sporadically detectable. CSF and plasma concentrations of ara-U were low in all samples.
Conclusions
The administration of intrathecal encapsulation cytarabine prolongs sustained tumor exposure to cytotoxic concentrations of cytarabine (>0.02 µg/ml) with a slow continuous release of cytarabine from the DepoFoamTM particles, so drug exposure is prolonged over time, resulting in lower peak cytarabine levels and a longer duration of exposure compared with standard cytarabine (Ara-C).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chamberlain M, Kormanik P (1998) Neoplastic meningitis: a guide to diagnosis and treatment. CNS Drugs 10:25–41
Olson ME, Chernik NL, Posner JB (1974) Infiltration of the leptomeninges by systemic cancer A clinical and pathologic study. Arch Neurol 30:122–137
Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772
Patchell RA, Posner JB (1985) Neurologic complications of systemic cancer. Neurol Clin 3:729–750
Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin 21:25–66
Shapiro WR (1975) Chemotherapy of primary malignant brain tumors in children. Cancer 35(3 suppl):965–972
Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG (1984) Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 35:826–830
Graham FL, Whitmore GF (1970) The effect of beta- D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res 30:2627–2635
Kim S, Chatelut E, Kim JC et al (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11:2186–2193
Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116
Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt®) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402
Jaeckle KA, Phuphanich S, Bent MJ et al (2001) Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84:157–163
Jaeckle KA, Batchelor T, O’Day SJ et al (2002) An open label trial of sustained-release cytarabine (DepoCyt®) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57:231–239
Chamberlain MC, Kormanik P, Howell SB, Kim S (1995) Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52:912–917
Blaney SM, Balis FM, Poplack DG (1991) Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Huntingt) 5:107–116 discussion 123, 127
Blaney SM, Balis FM, Poplack DG (1991) Current pharmacological treatment approaches to central nervous system leukaemia. Drugs 41:702–716
Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S (1993) Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101) A phase I study. Arch Neurol 50:261–264
Momparler RL, Onetto-Pothier N, Bouffard DY, Momparler LF (1990) Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. Cancer Chemother Pharmacol 27:141–146
Raijmakers R, de Witte T, Linssen P, Wessels J, Haanen C (1986) The relation of exposure time and drug concentration in their effect on cloning efficiency after incubation of human bone marrow with cytosine arabinoside. Br J Haematol 62:447–453
Muus P, Haanen C, Raijmakers R, de Witte T, Salden M, Wessels J (1987) Influence of dose and duration of exposure on the cytotoxic effect of cytarabine toward human hematopoietic clonogenic cells. Semin Oncol 14(suppl 1):238–244
Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN (2000) Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 46:382–386
Acknowledgement
Surasak Phuphanich, MD was supported in part by a Georgia Cancer Coalition Distinguished Clinical Investigator Professorial Award. We gratefully acknowledge the excellent editing assistance of Ms. Melissa Phuphanich.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was performed at Moffitt Cancer Center, Tampa, Florida and University of Florida College of Medicine, Gainesville, Florida. This work was presented in part at the 12th␣International Conference on Brain Tumor Research and Therapy at Keble College, Oxford, United Kingdom on September 20–23, 1997.
Rights and permissions
About this article
Cite this article
Phuphanich, S., Maria, B., Braeckman, R. et al. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81, 201–208 (2007). https://doi.org/10.1007/s11060-006-9218-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-006-9218-x